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Haris Charalambous1*, Athanasios Pallis2, Baktiar Hasan2 and Mary O’Brien3,4Abstract
Purpose: To examine availability of Palliative Care (PC) services and referral patterns of European Lung cancer specialists
to PC.
Methods: All members of the EORTC Lung Cancer Group (LCG) were asked via email to participate in an on-line survey.
Results: 50 out of 170 (29.4%) replied: 24 medical oncologists, 14 radiation/clinical oncologists, 11 pulmonologists and 1
thoracic surgeon. All but two of respondents (96%) had access to at least one component of PC services. In terms of
referral of patients to PC almost 75% of respondents would refer most of their patients when there were no treatment
options or at the end of life, while only 22% would refer patients at earlier stages of disease. Barriers for referral to PC
were negative attitudes of patients to PC (26%), lack of availability of PC services (20%), lack of expertise of PC physicians
(18%), the belief that referral to PC signifies abandoning patients (8%), and that PC specialists discourage active
oncological therapy (8%). Whilst most of the respondents expressed positive attitudes, 12-22% had overtly negative
attitudes towards PC. Seventy-eight (78%) of respondents expressed an interest to participate in a trial of early PC (EPC).
Conclusion: Despite good availability of SPC services at institutions of members of the EORTC LCG, and most
respondents expressing positive attitudes towards PC, their practice involved referral of patients to PC late in the
disease trajectory, hence Lung Cancer specialists in Europe have not adopted the practice of EPC concurrent with
active oncological care.
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According to a recent statement from the American
Society of Clinical Oncology (ASCO), Standard Oncology
Care (SOC) today remains focused on disease directed
therapy, often without realistic conversations about prog-
nosis, the potential benefits and limitations of disease-
directed therapy, and the potential role of Palliative Care
(PC) [1]. PC on the other hand, has a focus on providing
“active, holistic care of patients with advanced, progressive
illness, including management of pain and other symp-
toms, where provision of psychological, social and spirit-
ual support is paramount” [2]. Furthermore the goal of PC
is “achievement of the best quality of life for patients and
their families”, whilst “many aspects of PC are also* Correspondence: haris.charalambous@bococ.org.cy
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article, unless otherwise stated.applicable earlier in the course of the illness in conjunc-
tion with other treatments” [2].
Objective evidence of the benefits of early integration of
PC concurrent with SOC comes from a recent randomized
clinical study by Temel et al [3], who randomized patients
with advanced metastatic lung cancer to SOC combined
with Early Palliative Care (EPC) versus SOC alone. The
EPC used in this study was an active, intensive, at least
monthly visit with a palliative care consultant or specialist
nurse. Patients assigned EPC had a better quality of life,
with fewer patients experiencing depressive symptoms
than in the SOC group [3]. Median survival was longer
among patients receiving EPC, despite the fact that fewer
patients in the EPC group received aggressive end-of-life
care [3]. In response to the Temel study, Smith et al [4] in
an ASCO Provisional Clinical Opinion (PCO) reviewed
seven randomized studies examining the role of EPCCentral. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 SPC services available
Type of service Service available (n) %
Hospital based PC teams 39 78
Outpatient/community based PC teams 41 82
Inpatient hospice 34 68
All 27 54
None 2 4
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the importance and benefits of EPC in terms of improve-
ment of patients’ symptoms, quality of life and satisfaction,
whilst reducing caregiver’s burden, and made a firm
recommendation that EPC should be considered early
in the course of illness of all patients with advanced or
metastatic cancer [4].
In view of this evidence, this questionnaire was devised
to capture valid descriptive data regarding availability of
PC services in the respective European Centres, where
members of the European Organization of Research and
Treatment of Cancer (EORTC) Lung Cancer Group
(LCG) work, as well as attitudes and referral patterns of
Lung Cancer (LC) specialists to PC.
Methods
Survey sample/procedures
All members of the EORTC LCG were asked via email
to participate in an on-line survey to examine attitudes
and referral patterns to PC. All participants received a
group email introducing and explaining the study and
containing a link to the survey. No incentives were offered
for participation. A reminder was sent after approximately
4 and 8 weeks and the survey website was closed after
10 weeks.
Neither informed consent nor ethics committee approval
was deemed necessary for this study, given that this was
a survey of health care specialists and did not involve
research with human material or human data.
All statistical analyses, graphs and tables were per-
formed using SAS© Version 9.4 of the SAS System for
Windows [5]. Correlations between categorical variables
were assessed by Fisher exact test. This test is similar to
Chi-squared test but it is more robust to the existence
of empty cells or small sample size. Nevertheless, due
to a relatively low sample size in this study and with a
number of conducted tests, results of statistical tests
should be viewed as exploratory in nature and hence
should be interpreted with caution.
Questionnaire
The questionnaire was developed on the basis of existing
literature from similar surveys undertaken in the past
[6-9], and is available as Additional file 1.
Results
Participant characteristics
50 out of 170 (29.4%) EORTC LCG members from 40
out of 101 different EORTC centres, and from 14 of 21
countries replied.
There were 24 (48%) medical oncologists, 12 (24%)
radiation oncologists, 11 (22%) pulmonologists, 2 (4%)
clinical oncologists and 1 (2%) thoracic surgeon.Most of respondents’ practice involved the care of pa-
tients with metastatic cancer: for 15 (30%) of respondents
this involved most of their practice, whilst for 34 (68%) a
substantial proportion of their practice.
Availability of SPC services
Forty-eight respondents (96%) had access to at least one
component of SPC services, whilst 27 (54%) had access
to comprehensive SPC services. See results in Table 1.
Referral practices to PC
Participants were asked as to their general practice in
relation to PC referrals. The majority of responders
(72-76%) refer patients to PC when they have difficult to
control symptoms or when no more treatment options
are available, but only 12-20% of respondents refer all
patients or all symptomatic patients to SPC. All responses
are presented in Table 2.
Referral practices according to point in the Disease
Trajectory
Participants were asked as to their referrals to PC at
different times in the disease trajectory. Only 12%-22%
of participants refer almost all or most of their patients
to SPC at diagnosis of metastatic disease and during
oncological treatment. This increases to 75% when no
further oncological treatment is possible and at the end
of life. Results are presented in Table 3.
Barriers for referral to SPC
Participants were asked to rate on a Likert scale of 0 to
10 (0 = “would not be an issue for me” and 10 = “a very
significant issue for me”) about the degree to which six
(6) different statements/barriers affect their referral to
PC. Subsequently the results were grouped as follows:
0–1 strongly disagree, 2–4 disagree, 5 neutral, 6–8 agree,
9–10 strongly agree. Results are presented in Table 4.
Availability of PC physicians is a barrier for referral for
20% of respondents. The biggest barrier, expressed by
26% of respondents was that that their patients ‘do not
like being referred to PC’. Only 8% of respondents felt
that referral to PC signifies abandoning their patients,
and that PC specialists interfere or discourage active
oncological therapy. Finally only 18% of respondents had
concerns about the expertise of their PC colleagues.
Table 2 Referral practices to SPC
Referral to PC specialist Yes (n) %
Every patient 6 12
Every symptomatic patient 10 20
Patient with symptoms difficult to control 38 76
Patient with no more treatment options to PC team 25 50
Patient with no more treatment options to hospice directly 11 22
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Participants were asked to rate on a Likert scale of 0 to
10, the degree to which they feel SPC can help with the
following eight issues. Answers were subsequently grouped
as follows: 0–1 strongly disagree, 2–4 disagree, 5 neutral,
6–8 agree, 9–10 strongly agree. Results are presented in
Table 5.
For most issues regarding SPC, the majority of respon-
dents had positive attitudes, with only 12-26% negative
and 2-10% neutral views. However, regarding SPC’s role
to improve patients’ illness understanding and help with
all the above (questions 5 and 8), there was more dis-
agreement with 38% of respondents expressing negative
views and 4-10% being neutral.
Analysis was undertaken to examine whether there was a
correlation of responses (referral patterns and attitudes of
participants) according to services available to them. Re-
spondents were grouped into: group A: having full compre-
hensive (i.e. all) SPC services available to them, B: Some
SPC services and C: no SPC services available to them.
Respondents with comprehensive SPC services available to
them (group A) were more likely to refer patients to SPC
for patients with difficult to control symptoms, but their
practice did not differ significantly from the other respon-
dents, with less comprehensive SPC services available to
them(group B and C), in relation to referring all patients or
all symptomatic patients, or patients with no more treat-
ment options (Table 6). Regarding attitudes of respondents
towards SPC, according to availability of SPC services to
them, there were no statistically significant differences.
Finally seventy-eight (78%) of LC specialists expressed
an interest to participate in a trial randomizing EPC for
patients with metastatic lung cancer.
Discussion
The response rate to this survey (29.4%) although low
is similar to the ESMO survey [6] (34.4%) and theTable 3 Referral to PC according to point on the disease traje
Almost all Mos
At diagnosis 4.17% 8.33
During oncological treatment 8.16% 14.2
When no further treament available 39.58% 35.4
At end of life 58.33% 14.5Australian surveys by Ward [7] (30.3%) and Johnson [8]
(48%), although clearly lower than the Canadian survey
by Wendtland [10] (72%), where both emailed and mailed
invitations for participation were sent, and where a small
financial gift was also offered. In our survey a total of three
(3) emails were sent, and potentially a higher response rate
may have been achieved by sending also mailed invitations
and providing a small financial gift/voucher.
There was good availability of SPC services in centres
where EORTC LCG members work, with almost all (96%)
participants having access to at least one component of
SPC services, whilst more than half (54%) had access to
comprehensive SPC services. Similar data were seen in the
recent Canadian survey by Wendtland [10], where 94% of
oncologists had access to at least one component of an
SPC service, and 36% had access to comprehensive
services, and the Australian survey by Ward [7], where
96.5% of Australian medical oncologists reported access
to a SPC service. In contrast this differs from the ESMO
survey [6] undertaken almost 10 years ago, where only a
minority of European Medical Oncologists collaborated
often with a PC care specialist (35%), a palliative home
care service (38%) or an in-patient hospice (26%). This
difference may reflect both an improvement of availability
of SPC services in European countries over the last
10 years, and the fact that members of the EORTC Lung
Cancer Group work in large, academic centres more likely
to have SPC services. The availability of SPC in Europe,
Australia and Canada, is clearly better than in most
countries worldwide including the US [11], where less
than 60% of National Cancer Institute (NCI) Cancer
Centres have access to outpatient SPC, whilst in smaller
non NCI Cancer Centres such access is only 22% according
to data published in 2010 and 2011 [12]. The availability
of SPC in the developing world is clearly a much bigger
problem [13].
In terms of referral patterns of the EORTC Lung Cancer
members to SPC, there is a clear pattern of increasing
referrals towards the end of life. This was very consistent,
as when asked in two different ways (questions 5 and 6),
only 10-12% of respondents would refer their patients to
SPC at diagnosis of metastatic disease, whilst when no
further oncological treatment is possible and at the end of
life, between 72-76% of EORTC Lung cancer specialists
would refer almost all or most of their patients to SPC
(Tables 2 and 3). The conclusion is therefore that whilstctory
t Sometimes/often Rarely Never
% 16.67% 64.58% 6.25%
9% 36.73% 36.73% 4.08%
2% 18.75% 6.25% 0%
8% 18.75% 8.33% 0%
Table 4 Barriers for referral to SPC
Strongly disagree Disagree Neutral Agree Strongly agree
1. Palliative Care physicians are not available in my region/hospital 58% 18% 4% 14% 6%
2. Appointments with palliative care physicians are hard to get 58% 18% 4% 16% 4%
3. My patients do not like being referred to palliative care. 24% 36% 14% 24% 2%
4. Referring to palliative care physicians means that I abandon my patient 54% 34% 4% 2% 6%
5. Palliative care specialists discourage active oncological therapy 46% 40% 6% 8% 0%
6. Palliative care specialists in my country are not experienced/trained enough.
I can provide better symptom control management than them.
60% 20% 2% 12% 6%
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to SPC, most of these patients are in fact referred late in
the disease trajectory. This is very similar to the practice
of Canadian Oncologists [10]; 84% of them stated that
they refer terminally ill patients usually/always, and only
one third refer at the diagnosis of metastatic disease, with
only 13% referring at a prognosis of greater than 6 months
[10]. This however needs to be contrasted to the at least
theoretical preference of Australian Oncologists for a
concurrent rather than a sequential model of care, with
51.3% expressing a preference for concurrent manage-
ment introduced as complex care needs increase and
39.1% throughout the entire course of advanced cancer
[7], and the agreement that early referral is beneficial
(71%), and that patients may benefit from SPC services
while still receiving disease-modifying therapies (92%) [8].
The timing of referral to SPC is particularly important,
i.e. the issue of early PC (EPC) referral, given the benefits
seen in terms of survival, quality of life and depression in
the study by Temel et al [3] and the ASCO PCO advocat-
ing EPC for all patients with advanced cancer [4], i.e. a
concurrent model of delivery of active oncological and
PC. The alternative approach of a sequential model of
care, and hence a late referral to SPC may result in phys-
ical, psychosocial and spiritual-religious symptoms and
needs remaining unattended or potentially ineffectively
managed for longer. Late referrals also result in relatively
little time for SPC providers to deal with these symptoms
so close to the end of life, hence less likely to be effective
in addressing these symptoms. Furthermore late referralTable 5 Attitudes towards SPC
SPC can help with:
1. Patients physical, psychological and spiritual symptoms
2. Enhance quality of life and positively influence the course of illness
3. Caregivers education/support and help them deal with anxiety and distres
4. Provide respite care for caregivers
5. Improve patients’ illness understanding
6. Difficult communication issues (end of life discussions)
7. Provide end of life care
8. All of the aboveto PC, results in PC often being viewed as end of life care,
resulting in negative preconceptions towards PC, which is
the underlying reason for patients and relatives refusal to
be referred for PC. Hence another benefit from this early
referral to PC and a concurrent PC and oncological care
approach, is that it does away with the negative precon-
ceptions and stigma of PC being viewed as end of life care,
allowing for a smoother introduction to PC, without
‘abandonment’ by the oncologist [7].
The biggest barrier for referral to SPC in this survey
was negative attitudes of patients to PC (cited by 26% of
participants). It should be noted that this reflects the
respondents’ perception of this, and not the actual atti-
tudes of patients. Other barriers for referral to SPC in
this survey were the lack of availability of PC services
(20%), lack of expertise of PC physicians (18%), and
finally 8% of participants felt that referral to PC signifies
abandoning their patients, and that PC specialists interfere
or discourage active oncological therapy. Similarly in both
the Australian survey by Ward [7] and the Canadian study
[10] the biggest barrier for referral related to negative
attitudes of patients to PC, but at a much higher rate
than in our survey. In the Canadian study [10], 43% of
oncologists felt that their patients had a negative perception
of the term palliative care, whilst in the study by Ward,
“reluctance for referral” was reported by almost 70% of
patients (minor 60.9%, major 8.7%) and even higher by
families (minor 67%, major 7%). Other significant barriers
in this survey related to availability of SPC services: a
lack of inpatient beds (minor 27%, major 34.8%) andStrongly disagree Disagree Neutral Agree Strongly agree
12% 6% 8% 50% 24%
12% 4% 2% 66% 16%
s 14% 8% 10% 56% 12%
12% 10% 22% 46% 10%
18% 20% 10% 42% 10%
18% 8% 8% 50% 16%
12% 0% 2% 52% 34%
38% 0% 4% 50% 8%
Table 6 Referral patterns according to SPC services available
Referral to SPC according to available SPC Services available
Palliative care services available
All (Hospital based PC teams,







N (%) N (%) N (%)
Palliative care referral for all patients
No 23 (85.2) 19 (90.5) 2 (100.0) 0.7552
Yes 4 (14.8) 2 (9.5) 0 (0.0)
Palliative care referral for symptomatic patients
No 20 (74.1) 18 (85.7) 2 (100.0) 0.5735
Yes 7 (25.9) 3 (14.3) 0 (0.0)
Palliative care referral for all patients with diffiuclt to control symptoms
No 3 (11.1) 7 (33.3) 2 (100.0) 0.0060
Yes 24 (88.9) 14 (66.7) 0 (0.0)
Palliative care referral for outpatient review if no more treatment
options available
No 15 (55.6) 8 (38.1) 2 (100.0) 0.1676
Yes 12 (44.4) 13 (61.9) 0 (0.0)
Palliative care referral directly to the hospice if no more treatment
options available
No 19 (70.4) 18 (85.7) 2 (100.0) 0.3331
Yes 8 (29.6) 3 (14.3) 0 (0.0)
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take some referrals (minor 30.4%, major 30.4%)” [7]. In
the other Australian study by Johnson [8], the main
barrier for referral was the perception that the cancer
specialist could manage the symptoms (64.2%); whilst
also higher than in our study was the rate of specialists
feeling of abandoning the patient (19.8%) [8]. Hence
whilst similar barriers were expressed in all the other
surveys [6-8,10], these were reported at a much higher
rate than in this survey. This may reflect the increased
need of Lung Cancer (LC) patients for PC in view of
the heavy symptom burden and poor prognosis associated
with LC, and possibly a greater familiarity of LC specialists
with SPC services.
The fact that the biggest barrier to referral appears to
be the negative attitudes of patients towards PC, suggests
that indeed there are negative preconceptions among the
public towards PC, possibly due to an association with
Hospice Care and a perception that this is end of life
Care, “where people go to die”. In support of this,
comes the finding from the Canadian survey that one
third of Canadian Oncologists would be more likely to
refer to SPC earlier if it was renamed supportive care
[10]. Two studies from the M. D. Anderson Cancer Center
also showed that renaming PC to supportive care may
increase SPC referrals or facilitate earlier referrals. Fadul
et al [14] in a survey of 100 medical oncologists and 100midlevel providers found that more participants preferred
the name supportive care compared with palliative care
(57% vs 19%, p < 0.0001), and that participants expressed
an increased likelihood to refer patients on active primary
treatment (79 vs 45%, p < 0.0001) and advanced cancer
treatment (89 vs 69%, p < 0.0001) if PC was renamed
supportive care. The name PC compared with supportive
care was perceived more frequently as a barrier to referral,
decreasing hope and causing distress in patients and
families [14]. In a subsequent study from the same
group, following a name change for the service from
PC to supportive care, an increase in both inpatient
referrals and earlier referrals in the outpatient setting
was found [15].
A previous review by Ahmed et al [16], looking at
barriers to access and referral to PC, identified lack of
knowledge and education amongst health and social
care professionals, and a lack of standardized referral
criteria as key factors. It has also been suggested that
unfamiliarity of oncologists with SPC services, resulting
in oncologists not being aware of the potential impact of
SPC to meet the complex needs of patients with advanced
cancer, as well as perceptions of some oncologists, that
either nothing can be done about these issues or that
they can do all this by themselves, may be to blame
[17]. This has major consequences for both Oncological
and PC services, and the realization of a common goal
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address this unfamiliarity of Oncologists with PC and
SPC services, it is vital that clinical training programs
in PC are made compulsory for all oncologists (both
trainees as well as practicing oncologists) [18]. In fact
in the Canadian study by Wendtlandt et al., it was found
that “controlling for age and specialty, those who com-
pleted a rotation in palliative care during their residency
were twice as likely to refer before chemotherapy started
than during chemotherapy, corroborating previous evi-
dence that experience with SPC may influence referral
practices” [10]. Hence providing PC training for oncolo-
gists could improve patient care both directly by better
symptom control as a result of better PC skills of oncolo-
gists (oncologists providing basic PC) and indirectly by
increasing referrals to SPC services.
The majority of Lung Cancer specialists in this survey
expressed positive attitudes towards PC. There were
however up to 22% of participants who had overtly nega-
tive attitudes and this was similar to the ESMO survey,
where 15% had pervasively negative views [6].
The strengths of this study relate to the fact that it
provides more updated information regarding oncologists’
attitudes and referral patterns to SPC compared to the
previous important studies by Cherny et al [6], the two
Australian surveys by Ward et al [7] and by Johnson et al
[8], and the Canadian Oncologists survey by Wendtland
[10], which were undertaken prior to the Temel study [3]
and the ASCO PCO [4]. In addition in our study the views
of LC specialists were sought, to examine more specifically
the impact of the Temel study and the ASCO PCO on
their practice regarding referrals to PC. We can conclude
that as yet LC Specialists in Europe have not adopted an
EPC concurrent with active oncological care approach. A
possible explanation for this, may be that whilst it appears
that there is good availability of SPC services in European
centres, LC specialists may be either concerned that these
SPC services are currently fully utilized with limited
capacity to cope with more and earlier PC referrals, or by
conviction avoid to refer early to PC, unless absolutely
necessary e.g. due to extremely difficult to control symp-
toms (Table 6). It may also be that LC specialists are not
yet fully aware of, or are not convinced of the benefits of
EPC, which certainly applies for the 22% minority of
respondents with negative attitudes towards SPC. Finally
what may underlie this reluctance to adopt EPC is the
question regarding the reproducibility of the Temel study,
in other health care settings outside the US. This is in view
of concerns that the benefits seen with the Temel study
may relate to the relatively under-developed SPC services
in the US [11], and the different models of SPC provision
in the US compared to Australia, Canada and the UK. In
the US until now PC was considered to be synonymous
with hospice care and hence an option when patientsentered the terminal phase of their illness [7], although
there is a major effort to change this, e.g. with the ASCO
PCO [4]. In contrast in Canada, Australia, the UK and
some other European countries shared models of care with
concurrent PC and oncological care are more common.
There is therefore a need for further studies to provide
more evidence regarding the potential benefits of the
concurrent approach of EPC and SOC. The majority of
respondents in this survey expressed an interest to par-
ticipate in a European, multi-centre, multi-national study
of EPC.
Limitations of this survey include the low response
rate, which although similar to the previous Australian
and European surveys [6-8], is just under 30%. There is
therefore a potential response bias (which applies to all
of the previous surveys as well) that responders were
more likely to be more familiar or in favour of referring
to SPC services, than those that failed to participate in
this survey, and hence their answers may reflect a more
pro-PC view. Furthermore the members of the EORTC
Lung Cancer Group surveyed, are more likely to work in
large European tertiary Oncology Centres, and likely to
have better access to PC services than Oncologists work-
ing in smaller Oncology centres. Finally there is a potential
response bias due to LC specialists being aware of the
Temel study and ASCO guidelines, providing more ideal
answers than what their actual practice is. All these three
factors could potentially bias the survey towards providing
replies of earlier referral to SPC. However given that the
actual data in this survey show that referrals are made late
during the disease trajectory, even within the context of
good availability of SPC services, within large academic
centres and potentially even with LC specialists respon-
dents more interested in PC, this would give further
support to the findings of the study i.e. that a concurrent
model of care has not been adopted and that the recent
guidelines have not been translated into clinical practice
for LC patients in Europe.
Conclusions
This survey of European Lung Cancer (LC) specialists
found good availability of SPC services in the centres
where European LC specialists work. The majority of LC
specialists had positive attitudes towards SPC, whilst the
biggest barrier to referral was their perception that
patients do not like being referred to PC. In terms of
their referral patterns, LC Specialists refer most patients
to SPC, but predominantly late in the disease trajectory,
hence the practice of Early PC (EPC) concurrent with
standard oncological care has not been adopted. Further
research in concurrent models of care, with PC delivered
concurrently with anticancer treatment, is warranted to
provide more evidence regarding the benefits of this
approach.
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